Activity of Oritavancin and Comparator Agents against Multidrug-resistant Staphylococcal and Streptococcal Isolates Responsible for Documented Infections in European Hospitals (2011-2013)

Oritavancin is a semisynthetic bactericidal lipoglycopeptide currently under regulatory review by the US-Food and Drug Administration and European Medicines Agency for the treatment of patients with acute bacterial SSTIs. This study was performed to assess the activity of oritavancin against multidrugresistant (MDR) staphylococcal and streptococcal pathogens recovered from European medical centres as part of the SENTRY Antimicrobial Surveillance Programme for 2011-2013.